Skip to content
EMBARC
Menu
  • HOME
  • ABOUT US
    • Management Committee
    • Industry Partners
    • Acknowledgements
    • EMBARC Members
    • Transparency Notice
  • News
  • RESEARCH
    • The European Bronchiectasis Registry
    • The Biobank i.e., The EMBARC-BRIDGE Study
    • Clinical Trials
      • GREAT-2
      • AIR-NET
      • ESCAPE
      • Support of Non-EMBARC Clinical Trials
    • The Bronchiectasis Genetics Initiative
      • GECCO
    • Treatment Responses
      • Inhaled Antibiotics (ORBIT-3/4)
    • Imaging
    • Disease Definitions
    • Primary Ciliary Dyskinesia
    • Standards of Care
    • Patient Reported Outcomes
      • Chronic Airways Assessment Test (CAAT)
      • Bronchiectasis Health Questionnaire (BHQ)
      • Licensing for use of PROMs
    • Publications
  • EDUCATION
    • Early Careers Area
    • For Respiratory Professionals
      • Severity Assessment Calculator
    • For General Practitioners
  • PATIENT AREA
  • EMBARC REGISTRY
  • Contact Us
University of Dundee > EMBARC > Support of Non-EMBARC Clinical Trials

Recent Posts

  • Clinical Trial led by EMBARC Reveals Potential of Novel Antibody Therapy against Pseudomonas in Patients with Bronchiectasis – Results from the GREAT-2 Study  
  • A breakthrough for bronchiectasis: the results of the Phase III ASPEN trial are published
  • Please help with this quick survey – closes 4th April 2025
  • ERS Congress 2025 – Amsterdam
  • 8th World Bronchiectasis Conference 2025 – Brisbane, Australia

Recent Comments

No comments to show.
 
Copyright EMBARC ©2025
Web Site Supported by HIC Services & University of Dundee ©2025
Youtube Linkedin